CN104321053A - ω-3脂肪酸酯组合物 - Google Patents

ω-3脂肪酸酯组合物 Download PDF

Info

Publication number
CN104321053A
CN104321053A CN201380027275.8A CN201380027275A CN104321053A CN 104321053 A CN104321053 A CN 104321053A CN 201380027275 A CN201380027275 A CN 201380027275A CN 104321053 A CN104321053 A CN 104321053A
Authority
CN
China
Prior art keywords
compositions
compositionss
omega
fatty acid
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380027275.8A
Other languages
English (en)
Chinese (zh)
Inventor
弗雷德里克·桑茨利奥
彼得·珀西卡纳
贾尼丝·卡卡切
穆罕德·达黑姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanzlio Kompani Co ltd
Original Assignee
Sanzlio Kompani Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47998519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104321053(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanzlio Kompani Co ltd filed Critical Sanzlio Kompani Co ltd
Priority to CN201811562944.2A priority Critical patent/CN109966279A/zh
Publication of CN104321053A publication Critical patent/CN104321053A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
CN201380027275.8A 2012-03-30 2013-03-11 ω-3脂肪酸酯组合物 Pending CN104321053A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811562944.2A CN109966279A (zh) 2012-03-30 2013-03-11 ω-3脂肪酸酯组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618161P 2012-03-30 2012-03-30
US61/618,161 2012-03-30
PCT/US2013/030211 WO2013148136A1 (en) 2012-03-30 2013-03-11 Omega-3 fatty acid ester compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811562944.2A Division CN109966279A (zh) 2012-03-30 2013-03-11 ω-3脂肪酸酯组合物

Publications (1)

Publication Number Publication Date
CN104321053A true CN104321053A (zh) 2015-01-28

Family

ID=47998519

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380027275.8A Pending CN104321053A (zh) 2012-03-30 2013-03-11 ω-3脂肪酸酯组合物
CN201811562944.2A Pending CN109966279A (zh) 2012-03-30 2013-03-11 ω-3脂肪酸酯组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811562944.2A Pending CN109966279A (zh) 2012-03-30 2013-03-11 ω-3脂肪酸酯组合物

Country Status (19)

Country Link
US (9) US9302017B2 (enExample)
EP (2) EP3072510B1 (enExample)
JP (1) JP6359517B2 (enExample)
KR (1) KR102193214B1 (enExample)
CN (2) CN104321053A (enExample)
AU (1) AU2013240427B2 (enExample)
CA (1) CA2867168A1 (enExample)
CO (1) CO7121328A2 (enExample)
DK (1) DK3072510T3 (enExample)
ES (1) ES2741560T3 (enExample)
HK (1) HK1204978A1 (enExample)
HR (1) HRP20191392T1 (enExample)
IL (3) IL249821B (enExample)
IN (1) IN2014DN08449A (enExample)
MX (1) MX359711B (enExample)
MY (1) MY189576A (enExample)
PT (1) PT3072510T (enExample)
RU (1) RU2633862C2 (enExample)
WO (1) WO2013148136A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108354919A (zh) * 2017-12-29 2018-08-03 广东海洋大学 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用
CN109789111A (zh) * 2016-09-21 2019-05-21 埃维克辛公司 药物组合物

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2632967T3 (es) 2008-09-02 2017-09-18 Amarin Pharmaceuticals Ireland Limited Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
LT2424356T (lt) 2009-04-29 2017-11-27 Amarin Pharmaceuticals Ireland Limited Stabili farmacinė kompozicija ir jos panaudojimo būdai
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
EP3072510B1 (en) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
CN104582698A (zh) 2012-06-29 2015-04-29 阿玛林制药爱尔兰有限公司 在接受抑制素治疗的受试者中降低心血管事件风险的方法
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) * 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016046680A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of liver metabolic diseases
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
CA2974321C (en) 2015-01-21 2023-09-05 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.-3 fatty acid
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
DE102015106095A1 (de) * 2015-04-21 2016-10-27 K. D. Pharma Bexbach Gmbh Neue Anwendung von Omega-3-Fettsäure(n)
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
CN116492339A (zh) * 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
CA3008774C (en) * 2015-12-18 2021-10-12 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2017158439A1 (en) * 2016-03-16 2017-09-21 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
EP3496709A4 (en) 2016-08-12 2020-04-08 Pharmako Biotechnologies PTY Limited OMEGA-3 COMPOSITIONS AND PROCEDURES
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20230038594A (ko) 2018-09-24 2023-03-20 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
CN113873896B (zh) * 2019-02-01 2025-02-14 马斯公司 猫科动物食品组合物
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
WO2021183749A1 (en) 2020-03-12 2021-09-16 Sancilio Fred D A composition comprising docosahexaenoic acid and egg yolk suitable for sickle cell disease treatment
US20230398088A1 (en) * 2020-10-30 2023-12-14 The Trustees Of The University Of Pennsylvania Lipid Prophylactic Brain Injury Treatment
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553136A (zh) * 2006-09-06 2009-10-07 可口可乐公司 稳定的多不饱和脂肪酸乳液及用于防止、抑制或降低多不饱和脂肪酸在乳液中降解的方法
WO2010103404A1 (en) * 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513008A (en) 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4992476A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Skin cleansing and moisturizing composition and method of using and preparing same
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB2230442B (en) 1989-02-16 1992-11-25 Nat Res Dev Controlled release device
US5320798A (en) 1993-02-17 1994-06-14 Exxon Chemical Patents, Inc. Method for processing polyolefins at high shear rates
US5585192A (en) 1995-10-02 1996-12-17 Eastman Chemical Company Waterborne polyolefin adhesion promoter
EP1039893B1 (en) * 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
US6121210A (en) 1998-03-12 2000-09-19 Dap Products Inc. Foamable silicone oil compositions and methods of use thereof
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
CA2383233C (en) 1999-09-21 2010-06-08 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
NO313076B1 (no) 1999-12-28 2002-08-12 Pronova Biocare As Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
AU2003238264B2 (en) 2002-06-18 2009-05-21 Dsm Ip Assets B.V. Stable emulsions of oils in aqueous solutions and methods for producing same
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
ES2541488T3 (es) 2003-08-25 2015-07-21 Foamix Pharmaceuticals Ltd. Espuma farmacéutica penetrante
EP1684739A4 (en) 2003-11-12 2006-12-06 Childrens Medical Center TREATMENT AND PREVENTION OF LIVER DISEASES RELATED TO PARENTERAL DIET (PN)
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
JP2007526943A (ja) 2004-03-04 2007-09-20 エイチティーエル ハイ − テック リピッズ リミテッド 構造化されたトリグリセリド類およびそれを含むエマルション類
WO2006007510A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
CN1870906A (zh) 2004-07-22 2006-11-29 德国阿奎诺瓦增溶技术有限公司 醚油和其他物质的溶解物
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
NZ552389A (en) 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
JP2008516890A (ja) 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
US9452150B2 (en) 2004-08-18 2016-09-27 Mochida Pharmaceutical Co., Ltd. Jelly composition
EP1782801A4 (en) 2004-08-27 2008-08-06 Senju Pharma Co EYEWASH FLUID FOR THERAPY DRY EYES
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CA2600429A1 (en) 2005-03-08 2006-09-14 Reliant Pharmaceuticals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
US20060223737A1 (en) 2005-03-25 2006-10-05 L'oreal Foaming O/W emulsion and use thereof in cosmetics
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
KR20080055963A (ko) 2005-09-29 2008-06-19 아레나 파마슈티칼스, 인크. 5-ｈｔ2ａ 세로토닌 수용체 조절제와 관련된 장애의 치료에유용한 5-ｈｔ2ａ 세로토닌 수용체 조절제의 제약 조성물
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
JP5113527B2 (ja) * 2005-11-11 2013-01-09 持田製薬株式会社 ゼリー組成物
PL1957041T3 (pl) 2005-11-22 2011-02-28 Nestec Sa Emulsja olej-w-wodzie i jej zastosowanie dla nadania funkcji
US7652068B2 (en) 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
US20080058418A1 (en) * 2006-09-06 2008-03-06 The Coca-Cola Company Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
US20080102131A1 (en) 2006-10-31 2008-05-01 Kaneka Corporation Particulate composition comprising bioactive substance and method of producing the same
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
WO2009009040A2 (en) 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
CN101380358B (zh) 2008-10-14 2012-12-19 沈阳药科大学 精制紫苏籽油脂肪乳注射液及制备工艺
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
JP5872453B2 (ja) 2009-04-17 2016-03-01 ナタク ファルマ エセ．エレ． フィタン酸含量が低く、ω−３脂肪酸に富む組成物
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CA2762939C (en) * 2009-05-22 2017-07-18 Mochida Phamaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
US20110045050A1 (en) 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
KR102354949B1 (ko) * 2009-10-23 2022-01-24 바스프 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제
WO2011060084A1 (en) 2009-11-10 2011-05-19 MyCell Holdings Limited Stabilized formulations of fatty acids
US20140004186A1 (en) 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
US20140017308A1 (en) * 2010-09-08 2014-01-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
US9415035B2 (en) 2010-09-17 2016-08-16 Maine Natural Health Company, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
HK1207966A1 (en) 2012-02-16 2016-02-19 布莱特赛德创新有限公司 Dietary and nutritional compositions and methods of use
EP3072510B1 (en) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553136A (zh) * 2006-09-06 2009-10-07 可口可乐公司 稳定的多不饱和脂肪酸乳液及用于防止、抑制或降低多不饱和脂肪酸在乳液中降解的方法
WO2010103404A1 (en) * 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789111A (zh) * 2016-09-21 2019-05-21 埃维克辛公司 药物组合物
CN109789111B (zh) * 2016-09-21 2021-11-16 埃维克辛公司 药物组合物
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
CN108354919A (zh) * 2017-12-29 2018-08-03 广东海洋大学 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用

Also Published As

Publication number Publication date
MX359711B (es) 2018-10-08
AU2013240427A1 (en) 2014-09-25
US20150328326A1 (en) 2015-11-19
EP2830602B1 (en) 2020-10-21
WO2013148136A1 (en) 2013-10-03
IL249821A0 (en) 2017-02-28
MX2014011596A (es) 2015-07-06
US20150328327A1 (en) 2015-11-19
RU2633862C2 (ru) 2017-10-18
KR20140145597A (ko) 2014-12-23
US20150328325A1 (en) 2015-11-19
IN2014DN08449A (enExample) 2015-05-08
US20150328153A1 (en) 2015-11-19
US9370585B2 (en) 2016-06-21
US9364562B2 (en) 2016-06-14
US20140348929A1 (en) 2014-11-27
US9364558B2 (en) 2016-06-14
CO7121328A2 (es) 2014-11-20
CN109966279A (zh) 2019-07-05
US9375490B2 (en) 2016-06-28
JP2015514083A (ja) 2015-05-18
US9364560B2 (en) 2016-06-14
DK3072510T3 (da) 2019-08-12
HRP20191392T1 (hr) 2019-12-27
US9364561B2 (en) 2016-06-14
PT3072510T (pt) 2019-08-22
ES2741560T3 (es) 2020-02-11
MY189576A (en) 2022-02-17
US20150328324A1 (en) 2015-11-19
RU2014141406A (ru) 2016-05-20
US20150328177A1 (en) 2015-11-19
US9302017B2 (en) 2016-04-05
US9364559B2 (en) 2016-06-14
EP3072510B1 (en) 2019-05-08
CA2867168A1 (en) 2013-10-03
HK1204978A1 (zh) 2015-12-11
IL234814A (en) 2017-11-30
US9302016B2 (en) 2016-04-05
US20150328178A1 (en) 2015-11-19
US20140348930A1 (en) 2014-11-27
KR102193214B1 (ko) 2020-12-18
EP3072510A1 (en) 2016-09-28
EP2830602A1 (en) 2015-02-04
JP6359517B2 (ja) 2018-07-18
IL249821B (en) 2019-04-30
AU2013240427B2 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
CN104321053A (zh) ω-3脂肪酸酯组合物
US10898458B2 (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228398A1 (en) Omega-3 fatty acid ester compositions
US11046909B2 (en) Omega-3 fatty acid ester compositions
US9480651B2 (en) Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20150125529A1 (en) Omega-3 Fatty Acid Ester Compositions
US20150132389A1 (en) Omega-3 Fatty Acid Ester Compositions
US20160235853A1 (en) Omega-3 fatty acid ester compositions
US20150125530A1 (en) Omega-3 Fatty Acid Ester Compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204978

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150128

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1204978

Country of ref document: HK